Q1 Earnings Estimate for Lantheus Issued By Brookline Cap M

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Equities researchers at Brookline Cap M issued their Q1 2026 EPS estimates for shares of Lantheus in a research note issued to investors on Wednesday, February 11th. Brookline Cap M analyst K. Dolliver forecasts that the medical equipment provider will earn $1.03 per share for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Brookline Cap M also issued estimates for Lantheus’ Q2 2026 earnings at $1.08 EPS and FY2026 earnings at $4.68 EPS.

A number of other brokerages have also recently commented on LNTH. Mizuho raised their target price on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Truist Financial boosted their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Stock Up 1.0%

LNTH opened at $69.38 on Monday. The firm’s 50 day simple moving average is $66.30 and its two-hundred day simple moving average is $59.38. The company has a market capitalization of $4.60 billion, a PE ratio of 29.15 and a beta of -0.08. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MGO One Seven LLC purchased a new stake in Lantheus during the 2nd quarter valued at approximately $274,000. Nordea Investment Management AB boosted its position in shares of Lantheus by 1.6% during the second quarter. Nordea Investment Management AB now owns 48,075 shares of the medical equipment provider’s stock worth $3,913,000 after acquiring an additional 737 shares during the last quarter. William Blair Investment Management LLC grew its stake in Lantheus by 7.7% during the second quarter. William Blair Investment Management LLC now owns 391,622 shares of the medical equipment provider’s stock valued at $32,058,000 after acquiring an additional 27,855 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Lantheus during the second quarter valued at $1,812,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in Lantheus by 7.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 10,551 shares of the medical equipment provider’s stock valued at $866,000 after acquiring an additional 746 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.